Latest Insider Transactions at Biohaven Pharmaceutical Holding CO Ltd. (BHVN)
This section provides a real-time view of insider transactions for Biohaven Pharmaceutical Holding CO Ltd. (BHVN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Biohaven Pharmaceutical Holding Co Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Biohaven Pharmaceutical Holding Co Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2022
|
Charles Conway Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,800
-7.52%
|
$221,400
$123.86 P/Share
|
|
Jan 06
2022
|
Charles Conway Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+13.55%
|
-
|
|
Jan 06
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
409
-4.49%
|
$50,307
$123.86 P/Share
|
|
Jan 06
2022
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
875
+8.76%
|
-
|
|
Jan 06
2022
|
John Tilton Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
551
-11.12%
|
$67,773
$123.86 P/Share
|
|
Jan 06
2022
|
John Tilton Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+20.15%
|
-
|
|
Dec 31
2021
|
Matthew Buten Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,323
-50.58%
|
$866,251
$137.81 P/Share
|
|
Dec 31
2021
|
Matthew Buten Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+50.0%
|
-
|
|
Dec 20
2021
|
Julia P Gregory |
SELL
Open market or private sale
|
Direct |
12,000
-100.0%
|
$1,500,000
$125.0 P/Share
|
|
Dec 20
2021
|
Julia P Gregory |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+50.0%
|
$276,000
$23.63 P/Share
|
|
Dec 20
2021
|
George C. Clark VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,915
-18.86%
|
$235,545
$123.84 P/Share
|
|
Dec 15
2021
|
Elyse Stock Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,919
-43.36%
|
$2,301,495
$105.8 P/Share
|
|
Dec 15
2021
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,919
+33.14%
|
$328,785
$15.81 P/Share
|
|
Dec 14
2021
|
Elyse Stock Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,939
-48.17%
|
$728,595
$105.02 P/Share
|
|
Dec 14
2021
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,939
+21.79%
|
$104,085
$15.81 P/Share
|
|
Dec 10
2021
|
James Engelhart Strategic Advisor |
SELL
Open market or private sale
|
Direct |
35,000
-32.68%
|
$3,570,000
$102.85 P/Share
|
|
Dec 10
2021
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+43.11%
|
-
|
|
Nov 29
2021
|
Declan Doogan |
SELL
Open market or private sale
|
Direct |
24,525
-1.38%
|
$2,746,800
$112.83 P/Share
|
|
Nov 26
2021
|
George C. Clark VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,318
-18.58%
|
$266,570
$115.55 P/Share
|
|
Nov 26
2021
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+28.62%
|
-
|
|
Nov 25
2021
|
Vlad Coric Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,075
-16.72%
|
$583,625
$115.55 P/Share
|
|
Nov 25
2021
|
Vlad Coric Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,950
+26.51%
|
-
|
|
Nov 25
2021
|
James Engelhart Strategic Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
1,715
-13.28%
|
$197,225
$115.55 P/Share
|
|
Nov 25
2021
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
3,700
+22.27%
|
-
|
|
Nov 25
2021
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,738
-15.19%
|
$199,870
$115.55 P/Share
|
|
Nov 25
2021
|
Kimberly Gentile SVP, Clinical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+24.69%
|
-
|
|
Nov 25
2021
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Payment of exercise price or tax liability
|
Direct |
1,305
-12.89%
|
$150,075
$115.55 P/Share
|
|
Nov 25
2021
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+22.85%
|
-
|
|
Nov 25
2021
|
Elyse Stock Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,599
-17.64%
|
$183,885
$115.55 P/Share
|
|
Nov 25
2021
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,375
+27.13%
|
-
|
|
Nov 25
2021
|
John Tilton Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
492
-12.59%
|
$56,580
$115.55 P/Share
|
|
Nov 25
2021
|
John Tilton Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+24.23%
|
-
|
|
Nov 25
2021
|
Charles Conway Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+13.1%
|
-
|
|
Nov 23
2021
|
Charles Conway Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,885
+21.71%
|
$315,665
$29.17 P/Share
|
|
Nov 23
2021
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,915
+20.4%
|
$61,280
$32.42 P/Share
|
|
Nov 16
2021
|
Declan Doogan |
SELL
Open market or private sale
|
Direct |
37,740
-1.37%
|
$4,377,840
$116.82 P/Share
|
|
Nov 16
2021
|
Declan Doogan |
BUY
Exercise of conversion of derivative security
|
Direct |
559,000
+8.75%
|
$12,857,000
$23.42 P/Share
|
|
Nov 15
2021
|
John W Childs |
BUY
Exercise of conversion of derivative security
|
Direct |
474,200
+2.25%
|
$10,906,600
$23.42 P/Share
|
|
Nov 10
2021
|
John W Childs |
BUY
Open market or private purchase
|
Direct |
5,000
+0.1%
|
$615,000
$123.03 P/Share
|
|
Mar 17
2021
|
John W Childs |
BUY
Open market or private purchase
|
Direct |
13,157
+0.51%
|
$999,932
$76.0 P/Share
|
|
Mar 02
2021
|
John W Childs |
BUY
Open market or private purchase
|
Direct |
10,000
+0.39%
|
$850,000
$85.14 P/Share
|
|
Jan 25
2021
|
John W Childs |
BUY
Other acquisition or disposition
|
Direct |
5,706
+0.23%
|
-
|
|
Jan 06
2021
|
Vlad Coric Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,802
-23.01%
|
$481,566
$83.38 P/Share
|
|
Jan 06
2021
|
Vlad Coric Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+33.15%
|
-
|
|
Jan 06
2021
|
Charles Conway Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,747
-14.86%
|
$145,001
$83.38 P/Share
|
|
Jan 06
2021
|
Charles Conway Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+24.18%
|
-
|
|
Jan 06
2021
|
James Engelhart Strategic Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
1,747
-15.94%
|
$145,001
$83.38 P/Share
|
|
Jan 06
2021
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+25.5%
|
-
|
|
Jan 06
2021
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,747
-18.51%
|
$145,001
$83.38 P/Share
|
|
Jan 06
2021
|
Kimberly Gentile SVP, Clinical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+28.43%
|
-
|